6283 related articles for article (PubMed ID: 19018742)
21. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
22. Reduced spinal bone mineral density in adolescents of an Ultra-Orthodox Jewish community in Brooklyn.
Taha W; Chin D; Silverberg AI; Lashiker L; Khateeb N; Anhalt H
Pediatrics; 2001 May; 107(5):E79. PubMed ID: 11331729
[TBL] [Abstract][Full Text] [Related]
23. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
Brown AJ; Zhong M; Finch J; Ritter C; Slatopolsky E
Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
[TBL] [Abstract][Full Text] [Related]
24. Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.
Piñera-Haces C; Izquierdo-Ortiz MJ; Martín-de Francisco ÁL; García-Unzueta MT; López-Hoyos M; Toyos C; Allende N; Quintela E; Arias M
Nefrologia; 2013 Jan; 33(1):77-84. PubMed ID: 23364629
[TBL] [Abstract][Full Text] [Related]
25. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
26. Sequential changes of biochemical bone parameters after kidney transplantation.
Reinhardt W; Bartelworth H; Jockenhövel F; Schmidt-Gayk H; Witzke O; Wagner K; Heemann UW; Reinwein D; Philipp T; Mann K
Nephrol Dial Transplant; 1998 Feb; 13(2):436-42. PubMed ID: 9509459
[TBL] [Abstract][Full Text] [Related]
27. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
[TBL] [Abstract][Full Text] [Related]
28. Correlation of FGF-23 With Biochemical Markers and Bone Density in Chronic Kidney Disease-Bone Mineral Density Disorder.
Hussain I; Tandi R; Singh G; Kaur G; Abhishek ; Dodda S; Patel D; Natarajan B; Maram T; Kedia A; Vempati R; Sahu S; Choubey U
Cureus; 2023 Jan; 15(1):e33879. PubMed ID: 36812096
[TBL] [Abstract][Full Text] [Related]
29. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
Ghazali A; Fardellone P; Pruna A; Atik A; Achard JM; Oprisiu R; Brazier M; Remond A; Morinière P; Garabedian M; Eastwood J; Fournier A
Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266
[TBL] [Abstract][Full Text] [Related]
30. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.
Delmez JA; Slatopolsky E
Am J Kidney Dis; 1992 Apr; 19(4):303-17. PubMed ID: 1562018
[TBL] [Abstract][Full Text] [Related]
31. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
32. Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids).
Middelkoop K; Micklesfield LK; Walker N; Stewart J; Delport C; Jolliffe DA; Mendham AE; Coussens AK; van Graan A; Nuttall J; Tang JCY; Fraser WD; Cooper C; Harvey NC; Hooper RL; Wilkinson RJ; Bekker LG; Martineau AR
J Bone Miner Res; 2024 Apr; 39(3):211-221. PubMed ID: 38477739
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria.
Okoye JU; Arodiwe EB; Ulasi II; Ijoma CK; Onodugo OD
Afr Health Sci; 2015 Sep; 15(3):941-8. PubMed ID: 26957985
[TBL] [Abstract][Full Text] [Related]
34. Renal osteodystrophy and aluminum bone disease in CAPD patients.
Gokal R
Clin Nephrol; 1988; 30 Suppl 1():S64-7. PubMed ID: 3052962
[TBL] [Abstract][Full Text] [Related]
35. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
36. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
Slatopolsky EA; Burke SK; Dillon MA
Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
[TBL] [Abstract][Full Text] [Related]
37. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
[TBL] [Abstract][Full Text] [Related]
38. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
Indridason OS; Quarles LD
Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
[TBL] [Abstract][Full Text] [Related]
39. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
